Literature DB >> 11484965

Chondrosarcoma of bone: an oncological and functional follow-up study.

J Bruns1, M Elbracht, O Niggemeyer.   

Abstract

We retrospectively analysed the course of 42 out of 45 patients suffering from different chondrosarcomas which were treated surgically. We found a prospective 5- and 10-year survival of 64% for both time intervals. Follow-up examination was possible in 21 of 45 patients. Most of them were staged as NED, one as AWD, and 8 of 45 were lost to follow-up. From 16 dead patients 12 died of the disease and 4 of unknown but not to tumor related reasons. Survival was depending significantly on the histopathological grade, and the stage according to Enneking's surgical staging system. Eleven out of forty-five patients developed metastases within a mean period of twelve months after surgery. The survival of these patients was significantly reduced. Patients with centrally located tumors exhibited a distinct but non-significant worse survival than those suffering from peripheral tumors. In 18% (8 of 45) recurrence of the tumor was evident within a mean period of 24 months (5-85). Functional evaluation was performed in 21 out of 28 alive patients. After a mean follow-up time of 72 months the mean score was 64% (23-100). Females exhibited a distinct but non-significant better result, the same was observed for peripheral locations compared to centrally located tumors. Regarding age, grade, and line of resection no tendency of any dependence was detected, but worst results were seen in those with a stage III tumor and dedifferentiated CS.

Entities:  

Mesh:

Year:  2001        PMID: 11484965     DOI: 10.1023/a:1011162118869

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  23 in total

Review 1.  Chondrosarcoma of the rib.

Authors:  Takehiko Shimoyama; Ryuta Suzuki; Katsuo Yoshiya; Yasushi Yamato; Teruaki Koike
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2003-04

Review 2.  Therapeutic molecular targets in human chondrosarcoma.

Authors:  Nuor Jamil; Sarah Howie; Donald M Salter
Journal:  Int J Exp Pathol       Date:  2010-10       Impact factor: 1.925

3.  Sixty percent 10-year survival of patients with chondrosarcoma after local recurrence.

Authors:  Patrick P Lin; Mohammed D Alfawareh; Akihiko Takeuchi; Bryan S Moon; Valerae O Lewis
Journal:  Clin Orthop Relat Res       Date:  2012-03       Impact factor: 4.176

4.  Risk factors for metastasis at presentation with conventional chondrosarcoma: a population-based study.

Authors:  Kehan Song; Xiao Shi; Xin Liang; Hongli Wang; Fei Zou; Feizhou Lu; Xiaosheng Ma; Jianyuan Jiang
Journal:  Int Orthop       Date:  2018-04-21       Impact factor: 3.075

5.  Dedifferentiated chondrosarcoma--a fatal disease.

Authors:  J Bruns; W Fiedler; M Werner; G Delling
Journal:  J Cancer Res Clin Oncol       Date:  2005-03-23       Impact factor: 4.553

6.  Can Machine-learning Techniques Be Used for 5-year Survival Prediction of Patients With Chondrosarcoma?

Authors:  Quirina C B S Thio; Aditya V Karhade; Paul T Ogink; Kevin A Raskin; Karen De Amorim Bernstein; Santiago A Lozano Calderon; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2018-10       Impact factor: 4.176

Review 7.  The clinical management of chondrosarcoma.

Authors:  Richard F Riedel; Nicole Larrier; Leslie Dodd; David Kirsch; Salutario Martinez; Brian E Brigman
Journal:  Curr Treat Options Oncol       Date:  2009-02-24

8.  Giant Chondrosarcoma of Proximal Humerus in an Adult Female Patient: A Case Report.

Authors:  C K Ng; A Azuhairy; L H Tan; A Nordin
Journal:  Malays Orthop J       Date:  2015-07

9.  Extended intralesional treatment versus resection of low-grade chondrosarcomas.

Authors:  Chad Aarons; Benjamin K Potter; Sheila C Adams; J David Pitcher; H Thomas Temple
Journal:  Clin Orthop Relat Res       Date:  2009-01-14       Impact factor: 4.176

10.  New clinically relevant, orthotopic mouse models of human chondrosarcoma with spontaneous metastasis.

Authors:  Jonathan Cm Clark; Toru Akiyama; Crispin R Dass; Peter Fm Choong
Journal:  Cancer Cell Int       Date:  2010-06-28       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.